Korean J Hepatol.  2008 Dec;14(4):519-524. 10.3350/kjhep.2008.14.4.519.

Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation

• Kim BK
• Kwon SY
• Ko SY
• Choe WH
• Lee CH
• Han HS
• Chang SH

• KMID: 1073304
• DOI: http://doi.org/10.3350/kjhep.2008.14.4.519

Abstract

Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon alpha-2a and ribavirin.

Keyword

Hepatitis C; Liver Transplantation; Cholestasis; Fibrosis

MeSH Terms

Antiviral Agents/*administration & dosage
Cholestasis, Intrahepatic/*diagnosis/pathology
Combined Modality Therapy
Hepacivirus/drug effects
Hepatitis C, Chronic/diagnosis/*drug therapy/pathology
Humans
Interferon Alfa-2a/*administration & dosage
*Liver Transplantation
Male
Middle Aged
Polyethylene Glycols/*administration & dosage
RNA, Viral/analysis
Recurrence
Ribavirin/*administration & dosage
Tomography, X-Ray Computed